Silo Pharma (Nasdaq:SILO), a developmental-stage biopharmaceutical company involved in novel therapeutics and drug delivery systems, announced on Thursday that it has received confirmation that it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The company's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
Silo Pharma's CEO, Eric Weisblum, said that the company remains confident about its progress toward a first-in-human clinical trial of lead drug SPC-15 targeting post-traumatic stress disorder (PTSD) and successfully advancing its AI agents platform, QwikAgents.
Silo Pharma focuses on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease.
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
Natera Signatera gains PMDA approval in Japan for colorectal cancer testing
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
Sanofi appoints new global head of Research & Development Pharma
Lakewood-Amedex expands intellectual property portfolio with Australian Bisphosphocin patent
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB